UPDATE - Nomura Securities Initiates Coverage on CIENA (CIEN) with a Buy; Compelling Story of Operating Leverage
Get Alerts CIEN Hot Sheet
Price: $392.48 --0%
Rating Summary:
26 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Rating Summary:
26 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Join SI Premium – FREE
UPDATE - Nomura Securities initiates coverage on CIENA (NASDAQ: CIEN) with a Buy. PT $20.00.
Analyst, Stuart Jeffrey, said, "A compelling story of operating leverage and a pure-play in optical transmission. Profile of growing technologies drives our forecast of 11% revenue 3-yr CAGR (vs. overall market at 3-5%). Scale benefits from the NT transaction should expand EBIT margins from 0% in FY12 to 8.5% / 11.5% in FY13E / FY14E vs. Street at 6.5% / 7.5%, respectively. Valuation is compelling at 6.9x EV/EBITDA in CY13E and 4.5x CY14E. We initiate with EPS estimates above consensus at $1.44 / $2.42 for FY13 / FY14 vs. Street at $0.86 / $1.14, respectively. Street estimates maybe skewed by convertible bond dilution, tax rate and limited broker estimates for FY14."
To see more ratings on CIEN, Click Here
Analyst, Stuart Jeffrey, said, "A compelling story of operating leverage and a pure-play in optical transmission. Profile of growing technologies drives our forecast of 11% revenue 3-yr CAGR (vs. overall market at 3-5%). Scale benefits from the NT transaction should expand EBIT margins from 0% in FY12 to 8.5% / 11.5% in FY13E / FY14E vs. Street at 6.5% / 7.5%, respectively. Valuation is compelling at 6.9x EV/EBITDA in CY13E and 4.5x CY14E. We initiate with EPS estimates above consensus at $1.44 / $2.42 for FY13 / FY14 vs. Street at $0.86 / $1.14, respectively. Street estimates maybe skewed by convertible bond dilution, tax rate and limited broker estimates for FY14."
To see more ratings on CIEN, Click Here
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham Starts Faeth Therapeutics (FTH) at Buy
- H.C. Wainwright Starts ImageneBio (IMA) at Buy
- William Blair Starts Tandem Diabetes Care (TNDM) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
NomuraSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share